
|Articles|October 1, 2003
Biologics Seek 'Equal Footing' to Current Therapy
New York - The safety and efficacy of the new biologic agents for psoriasis suggest a new treatment strategy that departs from the current stepwise approach, according to Craig L. Leonardi, M.D., clinical associate professor of dermatology, Saint Louis University School of Medicine in Missouri.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















